表紙
市場調査レポート

急性炎症:パイプライン製品の分析

Acute Inflammation - Pipeline Review, H1 2014

発行 Global Markets Direct 商品コード 271833
出版日 ページ情報 英文 50 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
急性炎症:パイプライン製品の分析 Acute Inflammation - Pipeline Review, H1 2014
出版日: 2014年06月15日 ページ情報: 英文 50 Pages
概要

急性炎症は、身体的外傷(負傷や手術など)に対する即時型反応で、通常は2時間以内に生じます。この自然防御プロセスによって、患部への血流が増加し、体液が滞留します。高熱、発赤、腫れ、機能喪失などの症状が見られます。治療には、非ステロイド性抗炎症薬、コルチコステロイド、鎮痛薬などが含まれます。

当レポートでは、急性炎症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

急性炎症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • BioLineRx, Ltd.
  • Actelion Ltd
  • Forest Laboratories, Inc.
  • Italfarmaco S.p.A.
  • Alligator Bioscience AB
  • Anacor Pharmaceuticals, Inc.
  • Omeros Corporation
  • Dompe Farmaceutici S.p.A.
  • Peptinnovate Limited

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • ACT-389949
  • ATL-1222
  • CGEN-856
  • ADC-1004
  • DF-2156A
  • Selective Inhibitor of Pro Inflammatory Cytokine
  • AN-3485
  • PIN-201104
  • Small Molecule Targeting GPR32 for Acute Inflammation
  • Distamycin Derivatives

パイプライン製品の最新動向

休止状態のプロジェクト

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5142IDB

Global Markets Direct's, 'Acute Inflammation - Pipeline Review, H1 2014', provides an overview of the Acute Inflammation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Inflammation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Inflammation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Inflammation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Inflammation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Inflammation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Inflammation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acute Inflammation Overview
  • Therapeutics Development
    • Pipeline Products for Acute Inflammation - Overview
    • Pipeline Products for Acute Inflammation - Comparative Analysis
  • Acute Inflammation - Therapeutics under Development by Companies
  • Acute Inflammation - Therapeutics under Investigation by Universities/Institutes
  • Acute Inflammation - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Acute Inflammation - Products under Development by Companies
  • Acute Inflammation - Products under Investigation by Universities/Institutes
  • Acute Inflammation - Companies Involved in Therapeutics Development
    • BioLineRx, Ltd.
    • Actelion Ltd
    • Forest Laboratories, Inc.
    • Italfarmaco S.p.A.
    • Alligator Bioscience AB
    • Anacor Pharmaceuticals, Inc.
    • Omeros Corporation
    • Dompe Farmaceutici S.p.A.
    • Peptinnovate Limited
  • Acute Inflammation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACT-389949 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATL-1222 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CGEN-856 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADC-1004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DF-2156A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Selective Inhibitor of Pro Inflammatory Cytokine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-3485 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PIN-201104 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule Targeting GPR32 for Acute Inflammation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Distamycin Derivatives - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Acute Inflammation - Recent Pipeline Updates
  • Acute Inflammation - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acute Inflammation, H1 2014
  • Number of Products under Development for Acute Inflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Acute Inflammation - Pipeline by BioLineRx, Ltd., H1 2014
  • Acute Inflammation - Pipeline by Actelion Ltd, H1 2014
  • Acute Inflammation - Pipeline by Forest Laboratories, Inc., H1 2014
  • Acute Inflammation - Pipeline by Italfarmaco S.p.A., H1 2014
  • Acute Inflammation - Pipeline by Alligator Bioscience AB, H1 2014
  • Acute Inflammation - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014
  • Acute Inflammation - Pipeline by Omeros Corporation, H1 2014
  • Acute Inflammation - Pipeline by Dompe Farmaceutici S.p.A., H1 2014
  • Acute Inflammation - Pipeline by Peptinnovate Limited, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Acute Inflammation Therapeutics - Recent Pipeline Updates, H1 2014
  • Acute Inflammation - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Acute Inflammation, H1 2014
  • Number of Products under Development for Acute Inflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top